Pharmacokinetics and Dose Escalation of the Heat Shock Protein Inhibitor 17-AAG in Combination with Bortezomib in Relapsed or Refractory Acute Myeloid Leukemia

This phase I study was conducted to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the heat shock protein 90 (HSP90) inhibitor 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib, and to provide pharmacokinetic data in relapsed or refractor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Walker, Alison R., Klisovic, Rebecca, Johnston, Jeffrey S., Jiang, Yao, Geyer, Susan, Kefauver, Cheryl, Binkley, Philip, Byrd, John C., Grever, Michael R., Garzon, Ramiro, Phelps, Mitch A., Marcucci, Guido, Blum, Kristie A., Blum, William
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3860322/
https://ncbi.nlm.nih.gov/pubmed/23256542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.760733
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados